Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mark FitzGerald

Showing results (201-210 of 325) with videos related to

Pageof 33
Sort By:
The European Respiratory Journal|August 25, 2018
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthmaEugene R Bleecker, Michael E Wechsler, J Mark FitzGerald, et al.
The Clinical Respiratory Journal|March 3, 2019
Diagnosis and management of asthma, COPD and asthma-COPD overlap among primary care physicians and respiratory/allergy specialists: A global surveyChristine Jenkins, J Mark FitzGerald, Fernando J Martinez, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 2, 2022
16-year trends in asthma hospital admissions in CanadaTae Yoon Lee, John Petkau, Nevrose Mangat, et al.
The European Respiratory Journal|June 11, 2021
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthmaMonica Kraft, Guy Brusselle, J Mark FitzGerald, et al.
Respiratory Research|July 20, 2019
Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>David M G Halpin, Eli O Meltzer, Wendelgard Pisternick-Ruf, et al.
The Lancet. Respiratory Medicine|November 13, 2018
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
JAMA|February 24, 2012
Does this patient with liver disease have cirrhosis?Jacob A Udell, Charlie S Wang, Jill Tinmouth, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 16, 2008
The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control statusHelen M McTaggart-Cowan, Carlo A Marra, Yaling Yang, et al.
The European Respiratory Journal|November 17, 2022
Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometryLouis-Philippe Boulet, Marie-Ève Boulay, Andréanne Côté, et al.
BMC Genomics|November 23, 2012
Decreased miR-192 expression in peripheral blood of asthmatic individuals undergoing an allergen inhalation challengeMasatsugu Yamamoto, Amrit Singh, Jian Ruan, et al.
Pageof 33

Showing results (201-210 of 325) with videos related to

Sort By:
Pageof 33
The European Respiratory Journal|August 25, 2018
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthmaEugene R Bleecker, Michael E Wechsler, J Mark FitzGerald, et al.
The Clinical Respiratory Journal|March 3, 2019
Diagnosis and management of asthma, COPD and asthma-COPD overlap among primary care physicians and respiratory/allergy specialists: A global surveyChristine Jenkins, J Mark FitzGerald, Fernando J Martinez, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 2, 2022
16-year trends in asthma hospital admissions in CanadaTae Yoon Lee, John Petkau, Nevrose Mangat, et al.
The European Respiratory Journal|June 11, 2021
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthmaMonica Kraft, Guy Brusselle, J Mark FitzGerald, et al.
Respiratory Research|July 20, 2019
Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>David M G Halpin, Eli O Meltzer, Wendelgard Pisternick-Ruf, et al.
The Lancet. Respiratory Medicine|November 13, 2018
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
JAMA|February 24, 2012
Does this patient with liver disease have cirrhosis?Jacob A Udell, Charlie S Wang, Jill Tinmouth, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 16, 2008
The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control statusHelen M McTaggart-Cowan, Carlo A Marra, Yaling Yang, et al.
The European Respiratory Journal|November 17, 2022
Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometryLouis-Philippe Boulet, Marie-Ève Boulay, Andréanne Côté, et al.
BMC Genomics|November 23, 2012
Decreased miR-192 expression in peripheral blood of asthmatic individuals undergoing an allergen inhalation challengeMasatsugu Yamamoto, Amrit Singh, Jian Ruan, et al.
Pageof 33